Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-exposure traditional Chinese medicine plus apatinib maintenance in extensive-stage small-cell lung cancer
ChiCTR2100045255Phase 2Completed
- Sponsor
- First Affiliated Hospital of Anhui Medical University
- Start
- Nov 2017
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib and Yiqi Jiedu Tongluo in small cell lung cancer (SCLC), sponsored by First Affiliated Hospital of Anhui Medical University. Primary endpoints: Progression-free survival, Overall survival and 4 more. Started Nov 2017; status: completed.
02
Drugs
RivoceranibYiqi Jiedu Tongluo
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2100045255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045255.